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Abstract
Objective The treatment strategy for aortic stenosis (AS)
has been changing due to newly developed valvular pros-
theses and trans-catheter aortic valve implantation (TAVI).
To determine the role of new modalities for AS with a
small aortic root, papers using the concept of prosthesis-
patient mismatch (PPM) were reviewed.
Methods First, to determine the cut-off value of the
indexed effective orifice area (IEOA) for defining PPM, the
studies of surgical aortic valve replacement (SAVR) with a
follow-up longer than 5 years and a patient number larger
than 500 were reviewed. Second, the papers comparing
TAVI and SAVR were reviewed. Furthermore, the preva-
lence of PPM was reviewed, with the addition of papers on
aortic root enlargement, sutureless AVR, and aortic valve
reconstruction with autologous pericardium.
Results and conclusion The results of the long-term sur-
vival after aortic valve replacement (AVR) have indicated
that an IEOA less than 0.65 cm2/m2 should be avoided in
all cases, whereas the indications for patients with an IEOA
between 065 and 0.85 cm2/m2 should be determined by
considering multiple factors. A large body size and
younger age have a significantly negative influence on the
long-term survival. In Asian population, the prevalence of
PPM was low, despite the fact that the size of the aortic
annulus was small. The IEOA after TAVI was larger than
after surgical AVR in population-matched studies. To
evaluate the role of TAVI and other modalities for a small
aortic root, studies with a longer follow-up and larger
volume are thus warranted.
Keywords Aortic valve replacement  Small aortic root 
Aortic root enlargement: trans-catheter aortic valve
implantation  Patient-prosthesis mismatch
Introduction
Multiple registries and publications indicate that the
number of aortic valve replacements (AVR) is increasing.
According to the annual report by The Japanese Associa-
tion for Thoracic Surgery, the number of isolated AVR
cases in Japan (concomitant coronary artery bypass inclu-
ded) increased from 4963 (2003) to 10,034 (2013), a more
than 100 % increase during the 10-year period [1, 2]. It is
expected that the number will continue to increase because
of the increase in an aging population and the increase in
comorbidity including hypertension, diabetes, or renal
failure requiring chronic hemodialysis. A small aortic root
remained a concern, especially in the Asian population
because of the patient’s small body size. In the days when
the availability of a small sized prosthesis was limited, the
procedure of choice for patients with a small aortic annulus
was AVR with aortic root enlargement (ARE) [3]. The
concept of prosthesis-patient mismatch (PPM), first pro-
posed by Rahimtoola et al. [4] and re-visited by Pibarot
et al. [5], provided the logical background to select the
proper sized prosthesis with the data of the indexed
effective orifice area (IEOA), derived from the EOA of the
prosthesis and the body surface area of the patient. Pibarot
et al. proposed to avoid an IEOA less than 0.85 cm2/m2 to
prevent PPM. The framework of PPM encouraged the use
of prostheses with a larger EOA, such as a stentless
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bioprosthesis, bioprosthesis made of heterologous peri-
cardium or mechanical prostheses designed for supra-an-
nular implantation. If no prosthesis was available to
prevent PPM, then ARE was indicated. Reflecting the
current practice of the treatment of AS, we cardiac sur-
geons are undeniably influenced by the data provided by
the concept of PPM. However, how solid is the concept and
how is it applied to new treatment strategies? To discuss
the issue of the treatment strategy of AS with the guidance
of PPM, several questions should be answered.
First, the validity of the concept of PPM should be
confirmed. When Pibarot proposed his framework, there
was no long-term data available to assess the cut-off point
of the IEOA for the definition of PPM. Second, using the
validated framework of PPM, selection of the prosthesis or
procedure including trans-catheter aortic valve implanta-
tion (TAVI) should be discussed. In this paper, I will
review the long-term studies of PPM after AVR. Next, with
the PPM data reinforced by the long-term results, I would
like to discuss and share the result of the current thera-
peutic options including surgical AVR (SAVR), TAVI,
ARE, and aortic valve reconstruction with autologous
pericardium.
Influence of PPM on long-term survival
The concept of prosthesis-patient mismatch (PPM) was first
proposed by Rahimtoola et al. in 1978 [4], the era of tilting
disc and/or ball-and-cage prostheses. In this paper, Rahim-
toola et al. foresaw the consequence of using prosthesis with
a small orifice area relative to the body size, which would
cause obstruction of the outflow and inflow of the ventricle.
The recent widespread prevalence of the concept of PPMhas
been brought about by the framework proposed by Pibarot
et al. [5]. They developed a comprehensive framework based
on the relationship between the IEOA and the mean pressure
gradient of the aortic valve prostheses. When it was plotted
on the X–Y planes, the relationship showed a fairly good fit
to an exponential curve. The curve indicated a steep increase
in the mean pressure gradient when the IEOA was less than
0.85 cm2/m2. Using this framework, numerous studies have
evaluated the hemodynamic performance of aortic valve
prosthesis after AVR. The problem, however, was that the
framework only provides mechanical relationship between
the IEOAand themean pressure gradient.WhenPibarot et al.
proposed the framework; they did not provide its conse-
quence on the long-term survival, a hard clinical end point.
Since then, several papers have examined the influence of
PPM on a late survival using various cut-off values of IEOA.
Table 1 summarizes the papers describing the long-term
results (follow-up longer than 5 years) of aortic valve
replacement with the data of the IEOA. Only papers with
study volumes larger than 500 patients are listed [6–13].
With the definition of PPM as an IEOA less than
0.85 cm2/m2, Flameng et al. [6], and Ruel et al. [12] did not
observe a difference in the long-term survival in the overall
population, except for patients with a reduced left ven-
tricular function [12]. However, Walther et al. [13] showed
a significant difference in the 8.5-year survival rate (76.8 vs
81 %) with a large number of patients (4131 patients).
They also showed that an IEOA less than 0.85 cm2/m2 was
a significant risk factor for adverse cardiac events.
Rao et al. [11] set the cut-off point of PPM as an IEOA
of 0.75 cm2/m2. They found a significantly worse 12-year
actuarial survival of 74 % with PPM compared to the
survival rate of 85 % in patients without PPM. Moon et al.
[10] also used the value of 0.75 cm2/m2. Although they
could not find a survival difference in the overall
Table 1 Definition of PPM and early and late survivals
Patient number PPM definition Influence of PPM on early survival Influence of PPM on late survival
Ruel et al. (2006) [12] 805 IEOA\ 0.85 N/A Yes for patients with impaired
LVEF
Flameng et al. (2006) [6] 506 IEOA\ 0.85 No No
Walther et al. (2006) [13] 4131 IEOA\ 0.85 Yes Yes in the 8.5-year survival
(77 vs 81 %, p\ 0.01)
Moon et al. (2006) [10] 1400 IEOA\ 0.75 No Yes in the 10-year survival if age
\60 years or BSA[ 2.1
Rao et al. (2000) [11] 2154 IEOA\ 0.75 Yes in 30 day mortality
(8 vs 5 %, p = 0.027)
Yes in the valve related 12 year
survival (75 vs 84 %, p = 0.004)
Garcia-Fuster et al. (2007) [8] 747 IEOA\ 0.65 No Yes with cardiac mortality
Howell et al. (2010) [9] 801 IEOA\ 0.60 No No
Florath et al. (2008) [7] 533 IEOA\ 0.60 N/A Yes in the 7-year survival
(52 vs 80 %, p = 0.009)
Numbers in square brackets indicate the reference number
IEOA indexed effective orifice area (cm2/m2), PPM prosthesis-patient mismatch, LVEF left ventricular ejection fraction
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population, the authors showed a worse survival if the
patient was young (age less than 60 years) or if the patient
was large (body surface area larger than 2.1 m2).
Several studies have used the cut-off value of IEOA as
0.60 or 0.65 cm2/m2 to define PPM. Howell et al. [9] found
no differences in the survival, however, the number of
patients with an IEOA less than 0.65 cm2/m2 in their series
was small (48 patients, 6 % of the total study population),
and the follow-up was relatively short (5 years) compared
to the other studies. Except for the paper by Howell et al.,
the remaining two studies [7, 8] using cut-off point of
0.65 cm2/m2 showed a significantly worse survival in the
long-term survival, which appears reasonable because an
IEOA less than or equal to 0.60 cm2/m2 is defined as
severe AS in the 2014 AHA/ACC guideline [14].
PPM has been subdivided into severe (IEOA less than
0.65 cm2/m2) and moderate (IEOA between 0.65 and
0.85 cm2/m2) [15]. Reviewing the above mentioned studies
in Table 1 with long-term results, I presume that it may be
useful to subdivide PPM further into severe (IEOA less
than 0.65 cm2/m2), moderate (0.65–0.75 cm2/m2), and
mild (0.75–0.85 cm2/m2). The studies indicate that severe
PPM should be avoided in all cases, whereas in patients
with moderate PPM (IEOA: 0.65–0.75 cm2/m2), the
selection of procedure and/or prosthesis should be made by
considering several factors, including the body size and
age, because an age less than 60 years or body surface area
larger than 2.1 m2 appears to have strong negative influ-
ence on survival. Regarding patients with mild PPM
(IEOA: 0.75–0.85), aggressive approaches, such as ARE
could be reserved, especially when the patient is fragile or
has comorbidities.
Prevalence of PPM in the era of TAVI
How often do we encounter patients with PPM? In Table 2
and Fig. 1, the prevalence data of PPM reported in the
studies are shown [6–13, 16–21]. In addition the data from
TAVI are listed. The prevalence of PPM was significantly
influenced by the type of prosthesis and by the method of
implantation.
In the sub-study of the PARTNER trial, the prevalence
of PPM was compared between TAVI and surgical AVR
(SAVR) [20]. The prevalence of PPM was significantly
reduced in TAVI compared to SAVR. The reason for the
reduced prevalence of PPM in TAVI may be due to the fact
that the TAVI device does not have a sewing rim and it can
take full advantage of the entire native valve orifice except
for the slim thickness of the device wall. Similar results
were obtained from other studies comparing SAVR and
TAVI. Regarding the prevalence shown in these papers
[16, 18, 20, 21], the prevalence of PPM with SAVR was
fairly high (Fig. 1; diamonds) compared to the results
obtained from paper about SAVR alone (Fig. 1: triangles).
Table 2 The relationship
between IEOA and the
prevalence of PPM
SAVR/TAVI Patient number IEOA
\0.60 \0.65 \0.75 \0.85
Walther et al. (2006) [13] SAVR 4131 2.3 % 29.0 %
Rao et al. (2000) [11] SAVR 2154 7.6 % 10.5 %
Nozohoor et al. (2007) [19] SAVR 1568 3.8 % 53.3 %
Howell et al. (2010) [9] SAVR 1418 10.6 %
Moon et al. (2006) [10] SAVR 1400 37.7 %
Ruel et al. (2006) [12] SAVR 805 40.3 %
Garcia-Fuster et al. (2007) [8] SAVR 747 3.9 % 27.7 %
Florath et al. (2008) [7] SAVR 533 28.0 % 80.0 %
Flameng et al. (2006) [6] SAVR 506 0.2 % 20.2 %
Kaminishi et al. (2013) [17] SAVR 3609 8.5 %
Takagi and Umemoto (2016) [21] TAVI 4000 8.0 % 35.1 %
Pibarot et al. (2014) [20] SAVR 270 28.1 % 60.0 %
Pibarot et al. (2014) [20] TAVI 304 19.7 % 46.4 %
Giannini et al. (2011) [16] SAVR 58 29.3 %
Giannini et al. (2011) [16] TAVI 58 8.6 %
Kamperidis et al. (2015) [18] SAVR* 39 22.5 % 67.5 %
Kamperidis et al. (2015) [18] TAVI 40 10.3 % 30.8 %
Numbers in square brackets indicate the reference number
IEOA indexed effective orifice area (cm2/m2), PPM prosthesis-patient mismatch, SAVR surgical aortic
valve replacement, TAVI trans-catheter aortic valve implantation, SAVR* data from sutureless bioprosthesis
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The higher prevalence of PPM in these studies may be due
to the fact that the SAVR populations were matched with
the TAVI populations, and the patient background was
different compared with the patients in studies about
SAVR only.
Takagi and Umemoto performed a meta-analysis to
evaluate PPM in TAVI studies [21]. They showed that the
prevalence of PPM after TAVI was 8, 27, and 35 %, for
severe PPM (IEOA less than 0.6 cm2/m2), moderate PPM
(IEOA 0.6–0.85 cm2/m2), and overall PPM (IEOA less
than 0.85 cm2/m2), respectively.
Of note is the paper studying the Japanese population by
Kaminishi et al. [17]. The prevalence of PPM was low in
Japanese patients (8.5 % for IEOA less than 0.85 cm2/m2:
Fig. 1, red filled triangle). The results indicated that
although the annulus diameter of Asian patients is small
compared to non-Asian patients, the small body size might
have resulted in the low prevalence of PPM. The average
body surface area in this study was 1.55 and 1.61 m2 with
and without PPM, respectively. These values are quite
smaller than the average body surface area of 1.87–1.94 m2
reported in a study from Europe [13]. In addition, the study
period was relatively recent (between January 2008 and
December 2009) in the study of Kaminishi et al. Accord-
ingly, currently available pericardial bioprostheses or
mechanical prostheses designed for supra-annular implan-
tation were used, which could provide sufficient opening
for small sized Asian patients.
Framework of PPM and currently available
modality for AS
Since Pibarot et al. proposed their framework of PPM [5],
several new prostheses or procedures have emerged, such
as stentless bioprostheses, bioprosthesis using heterologous
pericardium, supra-annular type mechanical prostheses,
TAVI and sutureless AVR.
The hemodynamic performance and survival results of
stentless bioprosthesis were superior to those of porcine aortic
bioprostheses [22, 23]. To implant stentless bioprostheses, a
sub-coronary technique or full-root technique must be used.
Both techniques require a longer ischemic time compared
with stented prosthesis. Emergence of stented bioprosthesis
using heterologous pericardium and mechanical prosthesis
designed for supra-annular implantation reduced the need
for stentless bioprosthesis, because the hemodynamic
performance was similar among these prostheses.
As mentioned in the previous section, the hemodynamic
performance of TAVI was superior to SAVR in a limited
patient population. This result, however, cannot be
extrapolated to the general population of AS to justify the
use of TAVI for patients with small aortic roots. Several
issues should be discussed before considering TAVI as an
alternative to treat AS patient for small aortic root.
Important issues to consider include the long-term results
and complications, such as paravalvular leakage, heart
conduction disturbance, vascular injury and fatal annulus
rupture. A cost benefit analysis of TAVI is also warranted.
In addition, the limitation associated with the usage of
the small-size TAVI device, which is related to vascular
access, should be mentioned. Currently (as of May, 2016),
the smallest TAVI device available in Japan is the 20 mm
Sapien XT (Edwards Lifesciences Limited, Irvine, CA,
USA), which requires a femoral artery of more than 6 mm
in diameter. In most cases, this requirement is not fulfilled
in patients who have a small body size. In addition, the
20 mm Sapien XT is indicated for patients with an annulus
of between 16 and 19 mm in diameter. Even with the small
body size of many Asian patients, few patients have an
annulus of between 16 and 19 mm in diameter. Some data
indicate that the number of Japanese patients treated with
the Sapien XT accounts for less than 10 % of the entire
Sapien series. Considering these circumstances, the author
assumes that TAVI has not played a major role as a
treatment alternative for small aortic annulus.
Although ARE is an established surgical procedure [24],
improvements in the hemodynamic performance of the aortic
valve prosthesis reduced the need for ARE [3]. Beckamann
et al. in Hanover performed a study comparing ARE and
SAVR using the sutureless prosthesis. The hemodynamic
performance of the implanted prosthesis was similar between





























Fig. 1 The relationship between the definition of PPM with IEOA
and the prevalence of PPM. Triangles (SAVR) depict the prevalence
reported from the paper studying the SAVR population only. Circles
(TAVI) represent the prevalence of PPM in patients with TAVI.
Diamonds (SVAR-T) represent the PPM prevalence of SAVR from
the paper comparing TAVI and SAVR. The same fill color indicates
that the symbols are from the same study. Note that the prevalence is
lower in TAVI compared to SAVR. The triangle filled in red
indicates the study of SAVR from the Japanese population Ref. [17],
which shows a low prevalence of PPM. Each data point corresponds
to the numbers presented in Table 2 (color figure online)
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Implantation of the sutureless bioprosthesis required shorter
ischemic and operative times. In this study, the median value
of the annulus diametermeasured at the time of operation was
19 mm with an average body surface area of 1.8 m2, which
yielded a projected IEOA of 0.66 cm2/m2. These data imply
that ARE was indicated due to the large body size. In Asian
population with small body size ARE may not be indicated
with a measured annulus diameter of 19 mm in most of the
patients with currently available prostheses.
Ozaki et al. reported a series of aortic valve recon-
struction with glutaraldehyde-treated autologous peri-
cardium [26]. The average surgical annular diameter of 416
patients with AS was 20.1 mm. They showed satisfactory
hemodynamic results including an average peak pressure
gradient of 14.3 mmHg after 5.5 years with a 5-year sur-
vival rate of 83.3 %. Because autologous pericardium is
sutured to the native aortic annulus, the EOA is expected to
include a fully opening valve with the given native annu-
lus. Further studies with a longer follow-up and larger
series with multicenter data are surely warranted for this
interesting approach.
Limitations
An important issue regarding the measurement of EOA
should be noted as a limitation of this study. In real-world
clinical practice, the predicted IEOA is calculated for each
patient based on the body surface area of the patient and
in vitro EOA data—in most cases, this is obtained from the
manufacturer. It is well known that individual postoperative
EOA is influenced not only by the type and size of the pros-
thesis but also by the surgical technique. For example, simple
interrupted sutures provide a larger EOA than the supra-an-
nular implantation technique, which uses horizontal mattress
sutures [27]. For this reason, it is preferable to collect the
postoperative EOA from each patient’s postoperative
echocardiography data. The reality is that very few studies
have used the postoperative echo data. In the present review
only [7] used postoperative echo data, while [8–10] used
in vitro data and [6] used intermediatemethod incorporating a
limited number of postoperative echo data. To take advantage
of the data provided in this review, it is advisable that each
surgeon analyzes the relationship between the EOA provided
by the manufacturer and the EOA of their own patients, as
determined by postoperative echocardiography.
Summary and conclusion
An accumulation of data indicates that in patients with AS,
postoperative PPM defined by the IEOA influences the
long-term survival, especially in patients with a large body
surface area and age less than 60 years. Because of the
improvement in hemodynamic performance of the cur-
rently available prostheses, the prevalence of PPM has
been reduced and the need for ARE may be decreasing.
Newly developed modalities including TAVI have shown
better hemodynamic performance, however, their role in
treating small aortic root has yet to be determined. Further
study with larger number of patients and longer follow-up
is warranted.
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